Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the ONWARDS 1–5 trials

Documents similaires

• Efficacy and safety of once‐weekly insulin icodec versus once‐daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials
  par: Hirotaka Watada, et autres
  Publié: (2024)
• Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials
  par: Peter Rossing, et autres
  Publié: (2025)
• Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5
  par: Tina Vilsbøll, et autres
  Publié: (2025)
• Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
  par: Xichen Tong, et autres
  Publié: (2026)
• Efficacy and safety of once‐weekly insulin icodec in type 2 diabetes: A meta‐analysis of ONWARDS phase 3 randomized controlled trials
  par: Sahana Shetty, et autres
  Publié: (2024)